Sphingolipid Isolation from Cordyceps via Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating autoimmune and allergic diseases are limited by adverse side effects and inefficiencies, and there is a need for effective compounds that can be isolated and identified from natural sources like Cordyceps with reduced side effects and cost-effective production.
Innovation Solution
A method involving solvent extraction and sequential chromatographic separation using aliphatic alcohols and halogenated hydrocarbons to isolate sphingolipid portions from Cordyceps, specifically sphingoid base, ceramide, glycosphingolipid, and phosphosphingolipid portions, followed by mass spectrometry for identification and formulation into pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional steroid therapies are used to treat autoimmune and inflammatory diseases, then therapeutic efficacy is achieved, but adverse side effects and contraindications increase
Solution Approach 1:
The patent extracts and isolates specific active constituents (sphingolipids, particularly myriocin and related compounds) from Cordyceps sinensis through systematic fractionation and chromatographic separation. This extraction of the beneficial immunosuppressive component allows treatment without the harmful side effects of conventional steroids, directly resolving the contradiction between efficacy and safety
Solution Approach 2:
The patent employs a cost-effective extraction methodology using readily available solvents and standard chromatographic techniques to isolate sphingolipids from Cordyceps sinensis. This approach provides an affordable alternative to expensive conventional therapies while maintaining therapeutic efficacy, addressing both safety and economic concerns
2Object-affected harmful factors
If Traditional Chinese Medicine based on plant materials is used, then side effects are reduced, but manufacturing complexity increases due to diverse components
Solution Approach 1:
The patent segments the complex mixture of Cordyceps sinensis components into distinct fractions through systematic chromatographic separation. By isolating specific sphingolipid fractions (chloroform-methanol-soluble, water-soluble) and further purifying them, the patent transforms a complex herbal preparation into standardized, isolated active constituents, reducing manufacturing complexity while maintaining the safety benefits of natural products
Solution Approach 2:
The patent replaces traditional complex herbal preparation methods with modern analytical and separation techniques including thin-layer chromatography, column chromatography, and mass spectrometry. This substitution of traditional mechanical/herbal processing with precise chemical separation methods simplifies manufacturing while preserving the therapeutic benefits of natural constituents
3Measurement precision
If sphingolipids are isolated from Cordyceps using conventional methods, then identification is achieved, but isolation efficiency and purity are insufficient
Solution Approach 1:
The patent performs preliminary fractionation of Cordyceps sinensis extracts into chloroform-methanol-soluble and water-soluble fractions before detailed chromatographic separation. This preliminary classification organizes the complex mixture into manageable groups, significantly improving subsequent isolation efficiency and purity while maintaining accurate identification of sphingolipid constituents
Solution Approach 2:
The patent systematically varies chromatographic parameters including solvent systems (chloroform-methanol-water, ethyl acetate, methanol), stationary phases (silica gel, C18 reverse phase), and detection methods (TLC visualization, mass spectrometry, NMR) to optimize both isolation efficiency and identification accuracy. By adjusting these parameters, the patent achieves high-purity sphingolipid isolation with complete structural characterization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively isolates immunosuppressive sphingolipids with exceptional immunosuppressive activity, demonstrating a significant potential for treating inflammatory diseases with reduced side effects and improved therapeutic efficacy.
Implementation Method 1
subjecting a Cordyceps material to a solvent extraction with at least a first and a second extracting solvent in order to obtain a sphingolipid crude extract, wherein the first and the second extracting solvent independently comprise an aliphatic alcohol and a halogenated hydrocarbon
Implementation Method 2
subjecting the sphingolipid crude extract to at least a first and a second chromatographic separation step for obtaining the sphingolipid portion, which first chromatographic separation step includes liquid chromatography with a stationary phase comprising an unmodified silica
Implementation Method 3
liquid chromatography with a stationary phase comprising an unmodified silica
Data Source
AI summary
A method of isolating at least one sphingolipid portion selected from a sphingoid base portion, a ceramide portion, a glycosphingolipid portion or a phosphosphingolipid portion from Cordyceps, in particular from wild-type Cordyceps, allows for obtaining sphingolipid portions having an increased amount of one of sphingoid bases, ceramides, glycosphingolipids or phosphosphingolipids. The sphingolipid portions isolated contained significant amounts of sphingolipids not reported so far, and possess exceptional immunosuppressive activities. A method of treating a subject suffering from an inflammatory disease like an autoimmune disease or an allergic disease includes administering sphingolipids isolated from Cordyceps, in particular from wild-type Cordyceps. A method of treating a subject suffering from an inflammatory disease includes administering certain sphingolipids to the subject. Still further in accordance with the present invention is a composition, in particular a pharmaceutical composition comprising at least one sphingolipid portion.